

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
25 June 2020 (25.06.2020)



(10) International Publication Number  
**WO 2020/128447 A1**

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/00 (2006.01)  
C07K 14/705 (2006.01) C07K 16/30 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/GB2019/053570

(22) International Filing Date:

17 December 2019 (17.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1820547.6 17 December 2018 (17.12.2018) GB

(71) Applicant: **OXFORD UNIVERSITY INNOVATION LIMITED** [GB/GB]; Buxton Court, 3 West Way, Oxford  
Oxfordshire OX2 0JB (GB).

(72) Inventor: **DAVIS, Simon John**; c/o The MRC Weatherall  
Institute of Molecular Medicine, John Radcliffe Hospital,  
Headley Way, Oxford Oxfordshire OX3 9DS (GB).

(74) Agent: **HGF LIMITED**; 4th Floor, Merchant Exchange,  
17-19 Whitworth Street West, Manchester Greater Man-  
chester M1 5WG (GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv))

(54) Title: MODIFIED ANTIBODIES

(57) Abstract: Provided herein are antibody construct molecules comprising (i) an Fc receptor binding site, (ii) an antigen-binding site and (iii) a spacer moiety located between (i) and (ii), wherein the spacer moiety serves to increase the distance between (i) and (ii) so as to reduce the agonistic activity of the molecule as compared to the antibody variant that lacks (iii). Disclosed are various antibodies that can be de-agonized by introduction of the spacer moiety. Of specific interest are agonistic check point targeting antibodies that are de-agonized by introduction of the spacer moiety.



WO 2020/128447 A1